CORRECTION -- AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results

Why It Matters

The results highlight a continuing decline in volume and profitability, forcing the firm to lean on capital raises and debt reduction to sustain operations and pursue its growth strategy in the competitive aesthetic market.

Key Takeaways

• FY2025 revenue fell 15.8% to $151.8 million.
• Net loss widened to $11.7 million versus $8.0 million prior.
• Adjusted EBITDA dropped to $12.5 million, below prior year.
• Debt reduced to $45 million after $14.8 million raise.
• FY2026 guidance targets flat revenue, modest EBITDA growth.

Pulse Analysis

AirSculpt’s FY 2025 performance underscores the pressure facing mid‑size aesthetic providers as consumer demand for body‑contouring procedures eases. A 15.8% revenue contraction and a 15.6% drop in case volume reflect both heightened competition and a slower rollout of complementary GLP‑1 weight‑loss therapies that the company hopes to leverage. The negative adjusted EBITDA in the fourth quarter signals that operating efficiencies have not yet caught up with the revenue shortfall, raising questions about margin sustainability.

To shore up its balance sheet, AirSculpt tapped its at‑the‑market offering program, raising $14.8 million and using the proceeds to retire $11.0 million of debt. This effort trimmed gross debt to roughly $45 million and left the firm with $8.4 million in cash, preserving borrowing capacity under its revolving credit facility. The debt reduction improves covenant compliance and provides financial flexibility for the planned go‑to‑market initiatives, including talent acquisition and new procedural offerings aimed at revitalizing same‑store sales.

Looking ahead, the company’s FY 2026 outlook of flat‑to‑slightly higher revenue and an adjusted EBITDA range of $15‑$17 million hinges on the success of its revamped market strategy and the anticipated positive shift in same‑store sales reported in early 2026. If AirSculpt can translate its operational improvements into higher case volumes, it may restore investor confidence and capture a larger share of the growing aesthetic and obesity‑solution market. However, continued volume weakness or execution missteps could keep the stock under pressure, making the upcoming quarterly results a critical barometer for the firm’s turnaround trajectory.